Why is Senores Pharma. falling/rising?

As of 24-Jul, Senores Pharmaceuticals Ltd is experiencing a significant rise in its stock price, currently at 678.65, reflecting an increase of 66.95 or 10.94%. The stock has shown strong performance today, having reached a new 52-week and all-time high of Rs 704.9, with an intraday gain of 15.24%. Over the past week, the stock has outperformed the sector by 10.86% and has recorded a 27.95% increase over the past month. The company has demonstrated healthy long-term growth, with net sales growing at an annual rate of 85.60% and operating profit at 130.72%. However, there are concerns regarding falling investor participation, as delivery volume has decreased by 26.91% against the 5-day average, and institutional investors have reduced their stake by 0.65%.
In the broader market context, Senores Pharmaceuticals has outperformed the Sensex, which has seen a slight decline of 0.09% over the past week, while the stock itself has gained 9.16%. This trend highlights the stock's strong performance relative to the market. Despite the positive financial indicators, such as the highest PAT and net sales reported in June, the stock's valuation is considered very expensive with a price-to-book ratio of 4, and a relatively low return on equity of 7.4%. These factors may contribute to mixed sentiments among investors, particularly institutional ones, who have better resources to analyze the company's fundamentals.